Exploring the biology of vascular calcification in chronic kidney disease: What's circulating?

Schoppet, M.; Shroff, R. C.; Hofbauer, L. C.; Shanahan, C. M.
February 2008
Kidney International;Feb2008, Vol. 73 Issue 4, p384
Academic Journal
Chronic kidney disease (CKD) is associated with fatal cardiovascular consequences in part due to ectopic calcification of soft tissues particularly arteries, capillaries, and cardiac valves. An increasing body of evidence from experimental studies and in vivo data suggest that (I) a mineral imbalance with hyperphosphatemia and high-circulating calcium × phosphate product, (II) a deficiency of systemic or local calcification inhibitors, (III) death or ‘damage’ of vascular smooth muscle cells (VSMCs), and/or (IV) phenotypic transformation of VSMCs to osteo/chondrocytic cells may all act in concert to initiate and sustain vascular calcification. In CKD patients inhibitory systems are overwhelmed by a multitude of agents that induce VSMC damage and cell death resulting in the release of vesicles capable of nucleating basic calcium phosphate. Studies with genetically altered mice have identified both local and systemic calcification inhibitors that act to maintain VSMC differentiation or regulate vesicle properties. However, for many of these proteins the mechanisms and sites of action are still under investigation. In particular, it is unclear whether factors present in the circulation have an inhibitory role there and whether circulating levels of these proteins influence or are indicative of underlying disease processes in individual patients. A greater understanding of the origins and roles of potential circulating inhibitors may result in novel strategies aimed at the prevention or reversal of the life-limiting calcifying vasculopathies seen in CKD patients.Kidney International (2008) 73, 384–390; doi:10.1038/sj.ki.5002696; published online 28 November 2007


Related Articles

  • Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Qunibi, Wajeh Y. // Kidney International Supplement;Jun2005, Issue 95, ps43 

    Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Cardiovascular calcification (CVC) is commonly encountered both in the general population as well as in patients with end-stage renal disease (ESRD). The etiology of CVC in...

  • Reply from the authors. Chertow, Glenn M.; Burke, Steven K.; Raggi, Paolo // Kidney International;Jan2003, Vol. 63 Issue 1, p383 

    Replies to critiques of the authors' unblinded study on vascular calcification in hemodialysis patients. End-stage renal disease; Calcium acetate; Calcium carbonate; Vitamin D.

  • Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria. Chetyrkin, Sergei V.; Kim, Daniel; Belmont, John M.; Scheinman, Jon I.; Hudson, Billy G.; Voziyan, Paul A. // Kidney International;Jan2005, Vol. 67 Issue 1, p53 

    Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: A potential therapy for primary hyperoxaluria.Background.Primary hyperoxaluria is a rare genetic disorder of glyoxylate metabolism that results in overproduction of oxalate. The disease is characterized by severe calcium oxalate...

  • Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Ayinuer Adijiang; Sumie Goto; Satsuki Uramoto; Fuyuhiko Nishijima; Toshimitsu Niwa // Nephrology Dialysis Transplantation;Jun2008, Vol. 23 Issue 6, p1892 

    Background. Stage 5 chronic kidney disease (CKD) is associated with enhanced aortic calcification. The aim of this study was to determine if the administration of indoxyl sulphate (IS), a uraemic toxin, stimulates the progression of aortic calcification. Methods. The rat groups consisted of (i)...

  • Plasma pyrophosphate and vascular calcification in chronic kidney disease. O'Neill, W. Charles; Sigrist, Mhairi K.; McIntyre, Christopher W. // Nephrology Dialysis Transplantation;Jan2010, Vol. 25 Issue 1, p187 

    Background. Pyrophosphate (PPi) is a potent inhibitor of vascular calcification and may be deficient in renal failure. We sought to determine whether plasma PPi is affected by dialysis or the mode of dialysis and whether it correlates with vascular calcification.

  • Nature of soft tissue calcification in uremia. Contiguglia, Sebastian R.; Alfrey, Allen C.; Miller, Nancy L.; Runnells, Donald E.; Le Geros, Racquel Z. // Kidney International;Sep1973, Vol. 4 Issue 3, p229 

    The chemical and crystalline composition of metastatic calcification was studied in 21 uremic patients. Nonvisceral calcification has a calcium/ magnesium/phosphorus (Ca: Mg: P) molar ratio of 30/1/18 and an apatitic x-ray diffraction pattern. The molar, ratio of Ca/Mg/P in 33 tissue specimens...

  • Vascular calcification: types and mechanisms. Valdivielso, J. M. // Nefrologia;2011, Vol. 31 Issue 2, p142 

    Vascular calcification has traditionally been considered to be a passive process that was associated with advanced age, atherosclerosis, uncommon genetic diseases and some metabolic alterations such as diabetes mellitus and end-stage kidney failure. However, in the last years, vascular...

  • Primary osteoblast-like cells from patients with end-stage kidney disease reflect gene expression, proliferation, and mineralization characteristics ex vivo. Pereira, Renata C; Delany, Anne M; Khouzam, Nadine M; Bowen, Richard E; Freymiller, Earl G; Salusky, Isidro B; Wesseling-Perry, Katherine // Kidney International;Mar2015, Vol. 87 Issue 3, p593 

    Osteocytes regulate bone turnover and mineralization in chronic kidney disease. As osteocytes are derived from osteoblasts, alterations in osteoblast function may regulate osteoblast maturation, osteocytic transition, bone turnover, and skeletal mineralization. Thus, primary osteoblast-like...

  • Vascular calcification in ESRD: Another cloud appears in the perfect storm—but highlights a silver lining? Towler, Dwight A. // Kidney International;Dec2004, Vol. 66 Issue 6, p2467 

    Presents an author's view on vascular calcification in end-stage renal disease (ESRD). Discussion on the cardiovascular consequences of ESRD; Association of vascular calcification with ESRD; Significance of serum calcium concentration for the pathobiology and clinical management of vascular...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics